A Study to Evaluate the Safety and Effectiveness of Q301 Cream in Adolescents and Adults with Mild to Moderate Atopic Dermatitis

What we are studying

The purpose of this study is to compare investigational topical treatment (Q301) 1.0 % and 1.4% to placebo and see what works better and is safe in people with atopic dermatitis (a skin condition that can cause skin to be red, itchy and inflamed). You will have a 2 in 3 chance in getting the investigational medication. Your study participation will last for up to 16 weeks with 7 visits to the study site.

Who is Eligible

  • All Genders
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 12+

Eligibility Criteria

  • Mild to moderate atopic dermatitis diagnosed at least 3 months prior to going on study. Atopic Dermatitis on at least 5% but not exceeding 35% of the body. Further Criteria will be discussed with the study team.

What is involved

  • Informed Consent Review; Review of Medical History; Physical Examinations; Phone Calls and/or Emails; Study Visits and Consultations; Surveys/Questionnaires Laboratory and Imaging Tests; Specimen Sample Collection; Diary/e-Diary Writing or Recordings; Use of Study Treatments or Placebo; After Study Follow-Up Activities

Compensation

Compensation will be discussed with the study team.

Contact Information

Study Coordinator
Pat Wagoner
Email
pwagoner@wakehealth.edu
Phone
(336) 716-3775
Principal Investigator
Steven Feldman

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.